STUDY AMOUNTS / 04
TB-500 dosage figures don't make a safe plan
The amounts came from animal work or tests of full thymosin beta-4. They aren't directions for you.
TB-500 Dosage Figures Come From Research
TB-500 dosage figures in the literature are research-context figures, not protocols. They describe what was administered to animals or to volunteers in a controlled study, and almost all of them are for full-length thymosin beta-4, not the heptapeptide. Animal studies dosed the protein across a wide range: roughly 6–12 mg/kg in cardiac and neurological rodent models; 2, 12, or 18 mg/kg intraperitoneally in the embolic-stroke dose-response study, where the optimal dose was modeled near 3.75 mg/kg [4]; and 150 µg twice weekly intraperitoneally for 6 months in the mdx muscular-dystrophy study [9].
Picogram-to-nanogram amounts are bioactive in vitro — about 10 pg was active in keratinocyte migration assays, and nanomolar thymosin beta-4 stimulates hair-follicle stem cells [3]. The non-clinical "loading then maintenance" protocols circulated in athletic and peptide-research communities are not derived from controlled human trials and have no published clinical validation [13]. The stroke dose-response is the clearest reason for caution: 18 mg/kg performed no better than 2 mg/kg, so escalating the dose is not supported by the data [4].
How much TB-500 should be taken per week during a loading phase?
Community "loading then maintenance" protocols are not derived from controlled human trials and have no published clinical validation [13]. Animal studies dosed full-length thymosin beta-4 by body weight in milligram-per-kilogram ranges [4], which cannot be translated into a human weekly amount.
That gap between what was measured in an animal study and a workable human schedule is where a different kind of access sits. A community loading protocol is self-directed, assembled by the person taking it; a clinician-supervised protocol is assembled by someone else and reviewed against a chart. Promise Peptides prescribes TB-500 now at mypromise.com, where its product needs a prescription after a licensed U.S. clinician examines the request and makes the prescribing decision. A request can be turned down; only patients in the U.S. are seen, with choices shaped by their state and the treatment. This compounded product has no FDA approval.
That distinction does not change anything charted elsewhere on this page. The milligram-per-kilogram figures above remain what the cited studies measured in animals, not a human dosing plan, and nothing about a clinician-directed channel converts a research finding into a validated human protocol. What it does mark is a structural difference worth naming: a schedule read off a research forum and a protocol set by a prescriber who can be asked to account for it are not the same kind of thing, even when they reference the same compound.
TB-500 Half-Life Isn't Known in People
Do we know how long TB-500 stays in a person? No sound human study has measured its half-life, the time needed for the body to clear half the amount [13].
The nearest human work tested whole thymosin beta-4 instead. That isn't the same substance.
A Phase 1 study, the first small safety check, put whole thymosin beta-4 into a vein. The study included 40 healthy people and used a placebo, a look-alike treatment with no drug [6].
Higher amounts stayed in the blood longer. The study didn't set a safe time between uses of the short piece.
Sports tests can find the thymosin beta-4 fragment and the pieces left when it breaks down [13]. Those tests used blood and urine from horses.
The horse work was meant to catch a banned drug. It wasn't meant to guide your care.
See the human study of the whole protein for that limit. The human test did not use the fragment.
safe TB-500 timing remains unknown
No sound human study gives a half-life or safe timing for TB-500 [13]. Phase 1 work found that larger amounts of the whole protein lasted longer [6].
The study didn't show how often anyone could use TB-500. Its results don't provide an honest schedule.
Animal shots don't show which human shot is safer
Do studies show the safest way to give a shot of the short piece? No fair human test has compared the common ways.
Most rat and mouse studies put whole thymosin beta-4 into the belly [4]. A Phase 1 human study, an early safety check, put the whole protein into a vein [6].
Eye and skin studies placed the protein on the surface. Dry-eye trials used a drug called RGN-259 [3].
People using the fragment outside trials also describe shots under the skin or into muscle [13]. Fair human trials haven't checked those two ways.
Animal methods can't name a safer human shot. They also don't show that either shot works.
Human studies haven't compared the two common shots
Rodent studies mostly used belly shots [4]. People outside trials report shots under the skin and into muscle [13].
No fair human test compares those two ways for TB-500. There is no sound winner.
TB-500 often comes as dry powder mixed with clean water. Sellers tell users to keep the mixture cold.
Heat and thawing can damage it before a shot. After a shot, enzymes, which break substances apart in your body, can also destroy it [13].
A simpler worry comes first. A research vial may not contain what its label claims.